Previous 10 | Next 10 |
HOUSTON, Sept. 28, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that management will participate in two upcoming virtual conferences. Conference Details: ...
Bellicum Pharmaceuticals (BLCM) continues to be a disappointing investment as the share price consistently fails to rally despite the market hitting all-time highs. Since the start of the pandemic, my strategy has been to focus on biotechs and pharma that would have a hand in fighting the pand...
The following slide deck was published by Bellicum Pharmaceuticals, Inc. in conjunction with this Read more ...
Bellicum Pharmaceuticals, Inc. (BLCM) Q2 2020 Earnings Conference Call August 06, 2020, 17:00 ET Company Participants Stephen Jasper - Westwicke Partners Richard Fair - President, CEO & Director Atabak Mokari - CFO Conference Call Participants Nicholas Abbott - Wells Fa...
Bellicum Pharmaceuticals (NASDAQ: BLCM ) : Q2 GAAP EPS of -$8.55 misses by $5.68 . More news on: Bellicum Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Received FDA IND clearance to initiate Phase 1/2 clinical trial for BPX-603 for HER2+ solid tumors Initial data for BPX-601 cohort 5C to be presented at a medical meeting by the end of 2020 Management to host conference call and webcast today at 5 p.m. ET / 2 p.m. PT HOUSTON, A...
HOUSTON, July 30, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced it will report financial results for the second quarter 2020 after the close of U.S. markets on Thursday,...
The FDA has cleared Bellicum Pharmaceuticals' (NASDAQ: BLCM ) investigational new drug application (IND) for BPX-603. More news on: Bellicum Pharmaceuticals, Inc., Healthcare stocks news, Read more ...
HOUSTON, June 15, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced clearance by the U.S. Food and Drug Administration (FDA) of its investigational new drug application (IND...
NEW YORK, NY / ACCESSWIRE / June 3, 2020 / The Virtual Summer Summit will take place on June 9 th -12 th , connecting 47 presenting small and microcap companies with distinguished investors from around the globe. A full list of issuers are listed below along with webcasting links to view pre...
News, Short Squeeze, Breakout and More Instantly...
Bellicum Pharmaceuticals Inc. Company Name:
BLCM Stock Symbol:
NASDAQ Market:
Bellicum Pharmaceuticals Inc. Website:
Carisma Therapeutics Inc. (CARM) is expected to report $-0.56 for Q4 2023 First Acceptance Corp. (FACO) is expected to report for quarter end 2023-12-31 Bell Copper Corp (BCUFF) is expected to report for quarter end 2023-12-31 BioHarvest Sciences Inc (CNVCF) is expected to report for ...
First Solar Inc. (FSLR) is expected to report $3.19 for Q4 2023 VIZIO Holding Corp. Class A (VZIO) is expected to report $0.02 for Q4 2023 Henry Schein Inc. (HSIC) is expected to report $0.71 for Q4 2023 Republic Services Inc. (RSG) is expected to report $1.28 for Q4 2023 Forge Gl...
Kajima Corporation ADR (KAJMY) is expected to report for quarter end 2023-12-31 FaZe Holdings Inc. (FAZE) is expected to report for Q4 2023 BrewBilt MFG Inc (BBRW) is expected to report for Q4 2023 Correlate Energy Corp. (CIPI) is expected to report for Q4 2023 Hyzon Motors Inc. (...